Summary We have investigated in detail the effects of buthionine sulfoximine (BSO), a selective glutathione (GSH) depleting agent, on the GSH contents of a number of normal tissues and three experimental tumours in mice. Significant variations in the rate and degree of GSH depletion and recovery were observed among the normal tissues. Following a dose of 2.5 mmol kg-1 BSO, GSH nadirs were reached by approximately 5 h for the liver and kidney, 8 h for the lung and bone marrow, 12 h for red blood cells (RBCs) and by 24 h for the heart. The degree of depletion was greatest for the kidney (80%), liver (74%) and bone marrow (83%), intermediate for the heart (54%) and lung (40%), and least for RBCs (13%). Recovery of GSH content was fastest for the liver followed in descending order by the kidney, the lung, the bone marrow, RBCs and the heart. In contrast, the rate and extent of GSH depletion and recovery showed considerably less variation among the 3 murine tumours. In the tumours GSH nadirs were reached by 10-12h. The extent of depletion was about 55-65%. Recovery of GSH levels in the tumours required 48 h or more, a longer period than required by the liver, kidney and lung but shorter than that needed for the bone marrow, heart and RBCs. Attempts to preferentially deplete tumour GSH by exploiting the differences in recovery rates between normal tissues and tumours were only partially successful. Multiple BSO dosing at 16 h intervals allowed the liver to recover between doses, but the recovery in the kidney, lung and bone marrow was only partial and no recovery was seen in the heart. Finally, dose-depletion relationship investigations showed that, with the exception of the lungs, GSH depletion could be achieved in tumours with doses of BSO lower than those required for normal tissues.
It is now widely accepted that glutathione (GSH) plays an
Materials and methods important role in the cellular defence against cytotoxic insults. Some tumour cells cultured in vitro, in particular those of Mice and tumours human origin, were recently shown to contain extremely high levels of GSH (Biaglow et al., 1983; Mitchell et al., 1985) . The
All experiments were performed on 8-12 week-old inbred, possible relevance of GSH in cancer chemotherapy and the female C3H/HeJ mice (Jackson Lab., Bar Harbor, ME). The development of resistance during the course of treatment was murine sarcoma KHT (Kallman et at., 1967) and RIF-1 emphasized by the findings that tumour cells made resistant (Twentyman et al., 1980) , and the mammary carcinoma 1i6C to some anti-cancer drugs, e.g. melphalan, cis-platin and (Corbett et at., 1978) were grown in the gastrocnemius adriamycin, have increased cellular GSH concentrations muscle. Tumour-bearing mice were given BSO when tumours (Suzukake et al., 1982; Green et al., 1984; Hamilton et al., were between 250-350mg.
1985). For these reasons much current interest has focused on techniques of reducing cellular levels of GSH prior to Drug administration treatment with cytotoxic agents. The development of Buthionine sulfoximine (BSO), obtained in mixed buthionine sulfoximine (BSO) , a specific inhibitor of GSH enantiomeric form (DL-buthionine-SR-sulfoximine) from synthesis, has removed much of the uncertainties due to Sigma Chemical Co., was dissolved in phosphate buffer unwanted side-effects that were associated with GSH solution, pH 7.4, and injected i.p. at 0.01-0.04 ml g-1 of depleting agents having less specificity. Recent in vitro mice. studies using human tumour cell lines have shown that depletion of cellular GSH by BSO can indeed increase the Sample preparation cytotoxicity of a variety of anti-cancer drugs (Green et al., 1984; Hamilton et al., 1985; Crook et al., 1986; Lee et was then expressed by flushing through with 1.0 ml cold greatly assist the planning of such clinical trials. Critical to saline using a needle and syringe. Marrows from the same such studies is a detailed knowledge of the GSH depletion group were pooled and syringed repeatedly to obtain a single kinetics of normal tissues compared to tumours. cell suspension. The suspension then was diluted Furthermore, since the dose-limiting normal tissues may appropriately and nucleated cells were counted using a differ from drug to drug, information on a wide spectrum of Coulter Counter/Channelyzer following lysis of RBCs with critical normal tissues is clearly needed. In this study, we Zapoglobin II (Coulter). Aliquots of the original suspension have investigated in detail the dose-response relationships were diluted with excess 3% glacial acetic acid to lyse and kinetics of GSH depletion by BSO in a range of normal unnucleated cells and were then centrifuged at lO00g for tissues and tumours in mice.
10mmn. The 0.72+0.11 (60) was modified from the method of Minchinton (1984) and Heart 1.11+0.07 0.511+0.09 (46) has been described previously (Lee et al., 1986 nadirs by -5 h. Intermediate rates of depletion were seen in The GSH contents of the normal tissues and tumours the lung and bone marrow with nadirs at 4-16h and 8-12h studied are listed on Table I . Among the normal tissues the respectively. The heart was depleted the most slowly with a liver was found to have the highest GSH concentration nadir in GSH at 24-72h. The extent of GSH depletion followed, in descending order, by the kidney, the lung, and following a single dose of BSO also differed significantly the heart. Among the three murine tumours studied the between tissues ( Figure 1 ; Table I ). The most severe KHT and RIF-1 sarcomas had similar GSH contents, depletion occurred in the liver, kidney and bone marrow; the whereas the 16C mammary carcinoma had significantly less heart and the lung showed intermediate depletion, and RBCs GSH (Table I) .
showed the least depletion. Each datum point represents the average of 3 mice. Data are from 3 independent experiments. The initial GSH concentration for each normal tissue is given in Table I.   GLUTATHIONE DEPLETION BY BUTHIONINE SULFOXIMINE   35 and tumours was monitored at the time of the GSH nadir. 100 Figure 3 shows the data for the normal tissues and Figure this time GSH concentrations were at the nadir for tumours Time (hours) whereas in some normal tissues recoveries had already begun Figure 2 GSH contents as percent of initial concentration in 3 (Figures 1 and 2 ). Figure 5 shows the effects of giving 3 murine tumour models following a dose of 2.5mmolkg-1 BSO. initial GSH concentration for each tumour is given in Table I. of untreated control values after 3 doses of BSO. The most rapidly recovering organ, the liver, recovered fully 16 h after various tissues following a single dose of BSO also differed the third dose. The lung, kidney and bone marrow recovered considerably ( Figure 1) . Recovery, to pretreatment values, more slowly reaching 58, 46 and 38% of control by this was most rapid for the liver (16h) followed by the kidney time. The heart, however, showed no recovery, and was (30h), the lung (32h), and bone marrow (72h). Recovery down to 20% of control GSH concentration. Finally, 16C was extremely slow for the heart ( > 96 h) and RBCs ( > 72 h).
tumours also showed little recovery with GSH Furthermore, for the lung and in particular the liver and concentrations reduced to 30% of control at this time. kidneys a pronounced 'overshoot' in GSH levels occurred during recovery, i.e. GSH concentrations rose significantly above those for untreated controls.
Unlike the considerable variation seen in normal tissues Discussion (Figure 1 ) the rate and extent of GSH depletion in the 3 murine tumours following a single dose of BSO The present results demonstrate considerable diversity in the (2.5 mmol kg-1) were similar ( Figure 2 and Table I) response of the various normal tissues and tumours to Recoveries, however, were more rapid in the KUT and RIF treatment with the specific GSH depleting agent BSO. Where necessary the absolute GSH levels can be deduced Time (hours) from the values of initial GSH content given in Table I . Figure 5 The effects of multiple BSO-dosing at 16h intervals on
In agreement with previous reports (Griffith and Meister, the GSH contents of various normal tissues and the 16C 1979; Moron et al., 1979; Hazelton and Lang, 1980) , the mammary carcinoma. Arrows indicate the time at which BSO GSH contents were found to differ widely among different was administered. Data are from 2 independent experiments. normal tissues in the mouse. The highest concentration, found in the liver, was approximately 7 times that observed in the lung and the heart (Table I) . Further the bone marrow not yet been fully examined. A major aim of the present has very low GSH content. Much less variation was seen in study was to attempt to delineate dosing and timing the 3 murine tumour models studied. The GSH contents in protocols which might result in differential depletion of the tumours were relatively high in comparison with most tumour GSH content. In this respect, the data presented normal tissues except for the liver and kidney (Table I ; revealed clear differences between normal tissues and Griffith & Meister, 1979) . Even higher GSH concentrations tumours which may be exploitable in the design of treatment have been observed in human tumour xenografts grown in regimens.
nude mice (Allalunis-Turner et al., unpublished results). The ultimate goal in the manipulation of GSH levels is to Because of accumulating evidence implicating GSH in the improve the therapeutic index of a treatment regimen. cellular defence against anticancer agents (for review see However, a rational treatment strategy design will not be Arrick & Nathan, 1984) , much effort has been focused on possible unless the relationship between the critical reducing cellular GSH contents prior to treatment. BSO, a parameters of GSH depletion and the resultant biological selective inhibitor of the GSH synthesis enzyme y-glutamyl effects are known. It is, for example, a matter of much cysteine synthetase is considered superior to other depleting current debate as to whether it is (i) the absolute GSH agents because of its specificity and lack of side-effects.
However, with a single high dose of BSO (2.5mmolkg-1), selective depletion of tumour GSH cannot be achieved ( Figure 1 vs. Figure 2) . Following such treatment, depletion was greater in the liver, kidney and bone marrow than in all 3 tumour systems studied (Table I) . This is in agreement with the results of Minichinton and coworkers (1984) who observed patterns of GSH depletion in the liver and kidney as well as in tumours very similar to those reported here. In addition, attempts at preferential tumour depletion through multiple BSO exposures showed that selection through differential recovery rates was not entirely successful ( Figure  5 ). In these multiple-dosing experiments GSH recovery in the liver was complete but recoveries in the lung, kidney and bone marrow were only partial. Furthermore, although with this treatment regimen, the GSH concentration of the 16C tumour could be severely reduced to 25% of pretreatment level, a similar reduction to 20% of initial concentration also was observed in the heart. This result was not unexpected because of extremely slow GSH recovery kinetics in this normal tissue (Figure 1 ). Since the heart is the dose-limiting tissue for the cytotoxic agent adriamycin (Lefrak et al., 1973) , caution should be exercised in any clinical trial considering the combination of adriamycin plus BSO so that cardiotoxicity is not enhanced through severe GSH depletion.
In contrast to the GSH kinetics investigations, the doseresponse data (Figures 3 and 4) showed differences in GSH depletion between tumour and normal tissues which might be exploited to minimize adverse depletion in normal tissues, in particular the heart (Figures 3 and 4) . The GSH content in the three tumour systems could be depleted considerably using lower doses of BSO than all normal tissues except the lungs. However, it remains to be seen whether such depletions are sufficient to enhance the tumoricidal effects of chemotherapeutic agents. If this were the case it may be possible to avoid or minimize GSH depletion in normal tissues by giving smaller doses of BSO. It should be noted that this approach will not be successful for the lung because of its greater sensitivity to BSO. However, by using multiple low dose schedules to take advantage of the faster recovery kinetics of the lung, coupled with the fact that depletion in the lung is less severe than in other tissues, adverse effects in the lung also may be avoided. Experiments to exploit this possibility are currently in progress.
The ability of BSO to potentiate the antitumour activity of chemotherapeutic agents has been demonstrated convincingly in vitro in human tumour lines for adriamycin (Hamilton et al., 1985; Lee et al., 1986) , melphalan (Hamilton et al., 1985; Green et al., 1984) , cis-platinum (Hamilton et al., 1985; Lee et al., unpublished) and activated cyclophosphamide (Lee et al., unpublished results). In vivo chemosensitization also has been reported for cyclophosphamide (Ono & Shrieve, 1986; Tsutsui et al., 1986) Russo and coworkers (1986) showed no effect of BSO on CFU-S survival and peripheral WBC counts following melphalan treatment. A similar result was found in our laboratory (Alliet and Siemann, in preparation). In Addition we have observed that a 2.5 mmol kg-I dose of BSO had no effect on the acute lethality of adriamycin (Lee & Siemann, in preparation) and no detectable effect on the lung toxicity of cyclophosphamide as measured by breathing rate or lung lavage protein assays (Allalunis-Turner et al., unpublished results). Evidence so far is thus supportive of the idea that the therapeutic index of some chemotherapeutic drugs may be improved by BSO. It must be emphasized, however, that much more in-depth studies using normal tissue toxicity models best suited for each particular cytotoxic drug should be carried out before combination therapy with BSO can safely be used in patients.
Finally, if BSO is to be used in patients, the important question which needs to be addressed is how to monitor GSH depletion. The present results clearly indicate that no single normal tissue is representative of all others. The best strategy may be to monitor the GSH content of the critical dose-limiting tissue. As this is clearly not practical for all tissues, an alternative may be to monitor two or more tissues with different GSH response profiles, such as RBCs and bone marrow.
In conclusion, the present results indicate that the optimal use of BSO with chemotherapeutic drugs requires the detailed knowledge of the GSH kinetics in normal tissues and in tumours. For some normal tissues consideration probably will need to be given to both dose-timing and doseselection in order to avoid severe GSH depletion.
